Geschatte realtime
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
1,385 USD | +1,84% | -0,94% | +11,84% |
Omzet 2024 * | 189 mln. 177 mln. | Omzet 2025 * | 171 mln. 161 mln. | Marktkapitalisatie | 285 mln. 267 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -63 mln. -59,04 mln. | Nettowinst (verlies) 2025 * | -63 mln. -59,04 mln. | EV/omzet 2024 * | 1,51 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 1,66 x |
K/w-verhouding 2024 * |
-4,69
x | K/w-verhouding 2025 * |
-4,74
x | Werknemers | 167 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 89,79% |
Recentste transcriptie over Akebia Therapeutics, Inc.
1 week | -2,16% | ||
Lopende maand | -25,68% | ||
1 maand | -37,33% | ||
3 maanden | -2,16% | ||
6 maanden | +63,88% | ||
Lopend jaar | +9,68% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
John Butler
CEO | Chief Executive Officer | 59 | 01-07-13 |
Tracey Vetterick
ADM | Chief Administrative Officer | - | 01-04-22 |
Michel Dahan
COO | Chief Operating Officer | 45 | 01-01-13 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Michael Rogers
BRD | Director/Board Member | 64 | 12-12-18 |
Adrian Adams
CHM | Chairman | 73 | 12-12-18 |
Director/Board Member | 65 | 16-02-21 |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
0.01% | 0 M€ | 0,00% | - |
Datum | Koers | Variatie | Volume |
---|---|---|---|
23-04-24 | 1,38 | +1,47% | 1 252 362 |
22-04-24 | 1,36 | 0,00% | 2 006 106 |
19-04-24 | 1,36 | -2,16% | 2 956 394 |
18-04-24 | 1,39 | 0,00% | 2 562 577 |
17-04-24 | 1,39 | -0,71% | 2 944 347 |
uitgestelde koers Nasdaq, 22 april 2024 om 22:00 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+9,68% | 285 mln. | |
-1,71% | 103 mld. | |
+2,49% | 96,73 mld. | |
-0,03% | 21,31 mld. | |
-16,61% | 21,21 mld. | |
-6,31% | 18,79 mld. | |
-42,14% | 16,37 mld. | |
-27,40% | 13,68 mld. | |
+1,44% | 13,44 mld. | |
+21,29% | 10,98 mld. |